Thrombotic microangiopathy

Transfusion and Apheresis Science

Volumn 45, Issue 2, 2011, Pages 119-123

  Mortzell M ^a   Berlin, G ^b   Nilsson, T ^c   Axelsson, C G ^d   Efvergren, M ^e   Audzijoni, J ^f   Griskevicius, A ^f   Ptak, J ^g   Blaha, M ^h   Tomsova, H ^h   Liumbruno, G M ⁱ   Centoni, P ^j   Newman, E ^k   Eloot, S ^l   Dhondt, A ^l   Tomaz, J ^m   Witt, V ⁿ   Rock, G ^o   Stegmayr, B ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f University Hospital   (Lithuania)

^g Department of Clinical Oncology   (Czech Republic)

^h UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

ⁱ SAN GIOVANNI CALIBITA FATEBENEFRATELLI HOSPITAL   (Italy)

^j University Hospital   (Italy)

^k ANZAC Research Institute   (Australia)

^l GHENT UNIVERSITY HOSPITAL   (Belgium)

^m CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

ⁿ UNIVERSITY OF VIENNA   (Austria)

^o Department of Haematology   (Canada)

more..

Author keywords

ADAMTS13; Hemolytic uremic syndrome; HUS; Thrombotic microangiopathy; TMA; TTP

Indexed keywords

ANTIBODY; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE ANTIBODY;

ARTICLE; FAMILY HISTORY; HEMOLYTIC UREMIC SYNDROME; HUMAN; PLASMAPHERESIS; PROGNOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA;

FEMALE; HEMOLYTIC-UREMIC SYNDROME; HUMANS; MALE; PURPURA, THROMBOTIC THROMBOCYTOPENIC; THROMBOTIC MICROANGIOPATHIES;

EID: 80053443675     PISSN: 14730502     EISSN: 18781683     Source Type: Journal    
DOI: 10.1016/j.transci.2011.07.002     Document Type: Article

References (43)

1. Moake J.L. Thrombotic microangiopathies. N Engl J Med 2002, 347(8):589-600.
2. Ruggenenti P., Ceruti M., Remuzzi G. Thrombotic microangiopathies, including Hemolytic Uremic Syndrome. Comprehensive clinical nephrology 2007, 343-352. Mosby Elsevier, Philadelphia, USA. 3rd ed. J. Feehally, J. Floege, R.J. Johnson (Eds.).
3. Remuzzi G., Ruggenenti P. Thrombotic Microangiopathies including Hemolytic Uremic syndrome. Comprehensive clinical nephrology 2000, Mosby, Harcourt Publisher Limited, London, 5.33.31-12. R.J. Johnson, J. Feehally (Eds.).
4. Stegmayr B., Korach J.M., Norda R., Rock G., Fadel F. Is there a need for a national or a global apheresis registry?. Transfus Apher Sci 2003, 29(2):179-185.
5. Moake J.L., Rudy C.K., Troll J.H., Weinstein M.J., Colannino N.M., Azocar J., et al. Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 1982, 307(23):1432-1435.
6. Moake J.L. Thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. Arch Pathol Lab Med 2002, 126(11):1430-1433.
7. Nguyen T.C., Han Y.Y., Kiss J.E., Hall M.W., Hassett A.C., Jaffe R., et al. Intensive plasma exchange increases a disintegrin and metalloprotease with thrombospondin motifs-13 activity and reverses organ dysfunction in children with thrombocytopenia-associated multiple organ failure. Crit Care Med 2008, 36(10):2878-2887.
8. Sadler J.E. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood 2008, 112(1):11-18.
9. Levy G.G., Nichols W.C., Lian E.C., Foroud T., McClintick J.N., McGee B.M., et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001, 413(6855):488-494.
10. Moake J. Thrombotic thrombocytopenia purpura (TTP) and other thrombotic microangiopathies. Best Pract Res Clin Haematol 2009, 22(4):567-576.
11. Au W.Y., Chan K.W., Lam C.C., Young K. A post-menopausal woman with anuria and uterus bulk: the spectrum of estrogen-induced TTP/HUS. Am J Hematol 2002, 71(1):59-60.
12. Stylianou K., Tsirakis G., Mantadakis E., Xylouri I., Foudoulakis A., Vardaki E., et al. Refractory thrombotic thrombocytopenic purpura associated with oral contraceptives and factor V Leiden: a case report. Cases J 2009, 2:6611.
13. Bell W.R., Braine H.G., Ness P.M., Kickler T.S. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med 1991, 325(6):398-403.
14. Rock G.A., Shumak K.H., Buskard N.A., Blanchette V.S., Kelton J.G., Nair R.C., et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991, 325(6):393-397.
15. Scully M., Cohen H., Cavenagh J., Benjamin S., Starke R., Killick S., et al. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br J Haematol 2007, 136(3):451-461.
16. Caramazza D., Quintini G., Abbene I., Malato A., Saccullo G., Lo Coco L., et al. Relapsing or refractory idiopathic thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: the role of rituximab. Transfusion 2010, 50(12):2753-2760.
17. Foley SR, Webert K, Arnold DM, Rock GA, Clark WF, Barth D, Sutton DM. A Canadian phase II study evaluating the efficacy of rituximab in the management of patients with relapsed/refractory thrombotic thrombocytopenic purpura. Kidney Int Suppl 2009(112):S55-58.
18. Kiss JF. Major Clinical Trials in Apheresis:TTP. In: ASFA (American Society For Apheresis) New Orleans; 2010.
19. Kavanagh D., Richards A., Atkinson J. Complement regulatory genes and hemolytic uremic syndromes. Annu Rev Med 2008, 59:293-309.
20. Kavanagh D., Richards A., Noris M., Hauhart R., Liszewski M.K., Karpman D., et al. Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome. Mol Immunol 2008, 45(1):95-105.
21. Jokiranta T.S., Zipfel P.F., Fremeaux-Bacchi V., Taylor C.M., Goodship T.J., Noris M. Where next with atypical hemolytic uremic syndrome?. Mol Immunol 2007, 44(16):3889-3900.
22. Besbas N., Karpman D., Landau D., Loirat C., Proesmans W., Remuzzi G., et al. A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. Kidney Int 2006, 70(3):423-431.
23. McGraw M.E., Lendon M., Stevens R.F., Postlethwaite R.J., Taylor C.M. Haemolytic uraemic syndrome and the Thomsen Friedenreich antigen. Pediatr Nephrol 1989, 3(2):135-139.
24. Garg A.X., Suri R.S., Barrowman N., Rehman F., Matsell D., Rosas-Arellano M.P., et al. Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression. Jama 2003, 290(10):1360-1370.
25. Rogers T.J., Paton J.C. Therapeutic strategies for Shiga toxin-producing Escherichia coli infections. Expert Rev Anti Infect Ther 2009, 7(6):683-686.
26. Noris M., Remuzzi G. Hemolytic uremic syndrome. J Am Soc Nephrol 2005, 16(4):1035-1050.
27. Safdar N., Said A., Gangnon R.E., Maki D.G. Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 enteritis: a meta-analysis. Jama 2002, 288(8):996-1001.
28. Karmali MA. Host and pathogen determinants of verocytotoxin-producing Escherichia coli-associated hemolytic uremic syndrome. Kidney Int Suppl 2009(112):S4-7.
29. Caprioli J., Noris M., Brioschi S., Pianetti G., Castelletti F., Bettinaglio P., et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 2006, 108(4):1267-1279.
30. Richards A., Kemp E.J., Liszewski M.K., Goodship J.A., Lampe A.K., Decorte R., et al. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc Natl Acad Sci U S A 2003, 100(22):12966-12971.
31. Rock G., Shumak K.H., Sutton D.M., Buskard N.A., Nair R.C. Cryosupernatant as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Members of the Canadian Apheresis Group. Br J Haematol 1996, 94(2):383-386.
32. Bennett C.L., Connors J.M., Carwile J.M., Moake J.L., Bell W.R., Tarantolo S.R., et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000, 342(24):1773-1777.
33. Tsai H.M., Rice L., Sarode R., Chow T.W., Moake J.L. Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura. Ann Intern Med 2000, 132(10):794-799.
34. Medina P.J., Sipols J.M., George J.N. Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Curr Opin Hematol 2001, 8(5):286-293.
35. Gervasoni C., Ridolfo A.L., Vaccarezza M., Parravicini C., Vago L., Adorni F., et al. Thrombotic microangiopathy in patients with acquired immunodeficiency syndrome before and during the era of introduction of highly active antiretroviral therapy. Clin Infect Dis 2002, 35(12):1534-1540.
36. Selleng K., Warkentin T.E., Greinacher A., Morris A.M., Walker I.R., Heggtveit H.A., et al. Very severe thrombocytopenia and fragmentation hemolysis mimicking thrombotic thrombocytopenic purpura associated with a giant intracardiac vegetation infected with Staphylococcus epidermidis: role of monocyte procoagulant activity induced by bacterial supernatant. Am J Hematol 2007, 82(8):766-771.
37. Dwyre D.M., Bell A.M., Siechen K., Sethi S., Raife T.J. Disseminated histoplasmosis presenting as thrombotic microangiopathy. Transfusion 2006, 46(7):1221-1225.
38. Vesely S.K., Li X., McMinn J.R., Terrell D.R., George J.N. Pregnancy outcomes after recovery from thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Transfusion 2004, 44(8):1149-1158.
39. Martin J.N., Bailey A.P., Rehberg J.F., Owens M.T., Keiser S.D., May W.L. Thrombotic thrombocytopenic purpura in 166 pregnancies: 1955-2006. Am J Obstet Gynecol 2008, 199(2):98-104.
40. Francis K.K., Kalyanam N., Terrell D.R., Vesely S.K., George J.N. Disseminated malignancy misdiagnosed as thrombotic thrombocytopenic purpura: a report of 10 patients and a systematic review of published cases. Oncologist 2007, 12(1):11-19.
41. Goplani K.R., Vanikar A.V., Shah P.R., Gumber M., Feroz A., Patel H.V., et al. Postrenal transplant hemolytic uremic syndrome/thrombotic microangiopathy: Ahmedabad experience. Transplant Proc 2008, 40(4):1114-1116.
42. Batts E.D., Lazarus H.M. Diagnosis and treatment of transplantation-associated thrombotic microangiopathy: real progress or are we still waiting?. Bone Marrow Transplant 2007, 40(8):709-719.
43. Ruggenenti P. Post-transplant hemolytic-uremic syndrome. Kidney Int 2002, 62(3):1093-1104.